TY - JOUR
T1 - Optimization of flare management in patients with rheumatoid arthritis
T2 - results of a randomized controlled trial
AU - Myasoedova, Elena
AU - Crowson, Cynthia S.
AU - Giblon, Rachel E.
AU - McCarthy-Fruin, Kathleen
AU - Schaffer, Daniel E.
AU - Wright, Kerry
AU - Matteson, Eric L.
AU - Davis, John M.
N1 - Funding Information:
This work was financially supported by a grant from Pfizer (Grant ID 15322005).
Publisher Copyright:
© 2019, International League of Associations for Rheumatology (ILAR).
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Introduction/objectives: To evaluate the effect of a flare management intervention guided by non-physician providers versus usual care between rheumatology visits on flare occurrence and rheumatoid arthritis (RA) disease activity. Methods: Adult patients with established RA (per 2010 ACR criteria, n = 150) were randomized to the intervention arm (n = 75) versus usual care (n = 75). The Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire was administered monthly during 24 months to all patients in the intervention arm to assess flare status. Telephone nurse-led counseling or an expedited visit with a rheumatology provider was offered to patients in the intervention arm who indicated they were in flare. Results: Patients in the intervention arm completed a median of 8.5 (range 1–24) questionnaires. RA flare was reported on 122 (19%) of these questionnaires; average FLARE-RA score, 4.72 on 0 (no flare) to 10 (maximum flare) scale. Patients preferred an expedited clinic visit with a rheumatology provider during 39 (32%) of flares. The majority of patients preferred to self-manage their flare (76, 62%); some patients received nursing advice on flare management over the phone (7, 6%). There were no differences in RA flare by OMERACT9 definition, DAS28-CRP, CDAI, SDAI, anti-rheumatic treatment change by rheumatology provider, or remission by CDAI between the study arms over 24-month follow-up. Conclusions: The flare management intervention did not have any major effect on flare occurrence or RA disease activity metrics over the 24-month follow-up. The majority of patients in the intervention arm preferred self-management to an expedited visit with their rheumatology provider. Trial registration: ClinicalTrials.gov Identifier: NCT02382783 (https://clinicaltrials.gov/ct2/show/NCT02382783)
AB - Introduction/objectives: To evaluate the effect of a flare management intervention guided by non-physician providers versus usual care between rheumatology visits on flare occurrence and rheumatoid arthritis (RA) disease activity. Methods: Adult patients with established RA (per 2010 ACR criteria, n = 150) were randomized to the intervention arm (n = 75) versus usual care (n = 75). The Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire was administered monthly during 24 months to all patients in the intervention arm to assess flare status. Telephone nurse-led counseling or an expedited visit with a rheumatology provider was offered to patients in the intervention arm who indicated they were in flare. Results: Patients in the intervention arm completed a median of 8.5 (range 1–24) questionnaires. RA flare was reported on 122 (19%) of these questionnaires; average FLARE-RA score, 4.72 on 0 (no flare) to 10 (maximum flare) scale. Patients preferred an expedited clinic visit with a rheumatology provider during 39 (32%) of flares. The majority of patients preferred to self-manage their flare (76, 62%); some patients received nursing advice on flare management over the phone (7, 6%). There were no differences in RA flare by OMERACT9 definition, DAS28-CRP, CDAI, SDAI, anti-rheumatic treatment change by rheumatology provider, or remission by CDAI between the study arms over 24-month follow-up. Conclusions: The flare management intervention did not have any major effect on flare occurrence or RA disease activity metrics over the 24-month follow-up. The majority of patients in the intervention arm preferred self-management to an expedited visit with their rheumatology provider. Trial registration: ClinicalTrials.gov Identifier: NCT02382783 (https://clinicaltrials.gov/ct2/show/NCT02382783)
KW - Flare
KW - Randomized controlled trial
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85068802610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068802610&partnerID=8YFLogxK
U2 - 10.1007/s10067-019-04664-5
DO - 10.1007/s10067-019-04664-5
M3 - Article
C2 - 31264032
AN - SCOPUS:85068802610
SN - 0770-3198
VL - 38
SP - 3025
EP - 3032
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 11
ER -